These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37315261)

  • 1. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
    Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
    JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial Efficacy of Selpercatinib in
    Subbiah V; Gainor JF; Oxnard GR; Tan DSW; Owen DH; Cho BC; Loong HH; McCoach CE; Weiss J; Kim YJ; Bazhenova L; Park K; Daga H; Besse B; Gautschi O; Rolfo C; Zhu EY; Kherani JF; Huang X; Kang S; Drilon A
    Clin Cancer Res; 2021 Aug; 27(15):4160-4167. PubMed ID: 34088726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
    Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selpercatinib in Patients With
    Drilon A; Subbiah V; Gautschi O; Tomasini P; de Braud F; Solomon BJ; Shao-Weng Tan D; Alonso G; Wolf J; Park K; Goto K; Soldatenkova V; Szymczak S; Barker SS; Puri T; Bence Lin A; Loong H; Besse B
    J Clin Oncol; 2023 Jan; 41(2):385-394. PubMed ID: 36122315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
    Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
    Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Lu S; Cheng Y; Huang D; Sun Y; Wu L; Zhou C; Guo Y; Shao J; Zhang W; Zhou J
    Ther Adv Med Oncol; 2022; 14():17588359221105020. PubMed ID: 35923928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
    Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
    J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
    Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
    Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Selpercatinib in
    Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
    N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS Protective Effect of Selpercatinib in First-Line
    Pérol M; Solomon BJ; Goto K; Park K; Nadal E; Bria E; Martin C; Bar J; Williams JN; Puri T; Li J; Uh MK; Lin BK; Zhou C
    J Clin Oncol; 2024 Jul; 42(21):2500-2505. PubMed ID: 38828957
    [No Abstract]   [Full Text] [Related]  

  • 11. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and Safety Analysis of Selpercatinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer-Results from the Japanese Subset of a Global Phase 1/2 Study].
    Nishio M; Ohe Y; Ohashi K; Toyozawa R; Satouchi M; Sekine N; Mori J; Enatsu S; Goto K
    Gan To Kagaku Ryoho; 2022 Jun; 49(6):669-675. PubMed ID: 35799394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Zheng X; Ji Q; Sun Y; Ge M; Zhang B; Cheng Y; Lei S; Shi F; Guo Y; Li L; Chen L; Shao J; Zhang W; Gao M
    Ther Adv Med Oncol; 2022; 14():17588359221119318. PubMed ID: 36062046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated
    Solomon BJ; Zhou CC; Drilon A; Park K; Wolf J; Elamin Y; Davis HM; Soldatenkova V; Sashegyi A; Lin AB; Lin BK; F Loong HH; Novello S; Arriola E; Pérol M; Goto K; Santini FC
    Future Oncol; 2021 Mar; 17(7):763-773. PubMed ID: 33150799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
    Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
    Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced
    Lu S; Zheng X; Sun Y; Huang D; Wu L; Ji Q; Zhou C; Zhou J; Guo Y; Ge M; Ding D; Shao J; Zhang W; Gao M; Cheng Y
    Ther Adv Med Oncol; 2023; 15():17588359231189429. PubMed ID: 37655205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
    Minchom A; Tan AC; Massarelli E; Subbiah V; Boni V; Robinson B; Wirth LJ; Hess LM; Jen MH; Kherani J; Olek E; McCoach CE
    Oncologist; 2022 Feb; 27(1):22-29. PubMed ID: 34523767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.